Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TT4UXPE)

DTT Name MHC class I NK cell receptor 2DL1 (CD158A)
Synonyms
p58.1 MHC class-I-specific NK receptor; p58 natural killer cell receptor clones CL-42/47.11; p58 NK receptor CL-42/47.11; Natural killer-associated transcript 1; NKAT1; NKAT-1; Killer cell immunoglobulin-like receptor 2DL1; CD158A; CD158 antigen-like family member A
Gene Name KIR2DL1
DTT Type
Clinical trial target
 [1]
BioChemical Class
Immunoglobulin
UniProt ID
KI2L1_HUMAN
TTD ID
T71928
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MSLLVVSMACVGFFLLQGAWPHEGVHRKPSLLAHPGPLVKSEETVILQCWSDVMFEHFLL
HREGMFNDTLRLIGEHHDGVSKANFSISRMTQDLAGTYRCYGSVTHSPYQVSAPSDPLDI
VIIGLYEKPSLSAQPGPTVLAGENVTLSCSSRSSYDMYHLSREGEAHERRLPAGPKVNGT
FQADFPLGPATHGGTYRCFGSFHDSPYEWSKSSDPLLVSVTGNPSNSWPSPTEPSSKTGN
PRHLHILIGTSVVIILFILLFFLLHRWCSNKKNAAVMDQESAGNRTANSEDSDEQDPQEV
TYTQLNHCVFTQRKITRPSQRPKTPPTDIIVYTELPNAESRSKVVSCP
Function Receptor on natural killer (NK) cells for some HLA-C alleles such as w4 and w6. Inhibits the activity of NK cells thus preventing cell lysis.
KEGG Pathway
Antigen processing and presentation (hsa04612 )
Natural killer cell mediated cytotoxicity (hsa04650 )
Graft-versus-host disease (hsa05332 )
Reactome Pathway
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell (R-HSA-198933 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
3 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
IPH-2101 DMDUVCZ Multiple myeloma 2A83 Phase 2 [1]
IPH-2102 DMPBR0D Acute myeloid leukaemia 2A60 Phase 2 [1]
mab 1-7F9 DMQOBH4 Multiple myeloma 2A83 Phase 2 [2]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This DTT
Disease Name ICD 11 Studied Tissue p-value Fold-Change Z-score
Multiple myeloma 2C82 Bone marrow 2.29E-06 -0.43 -4.42
Acute myelocytic leukaemia 2C82 Bone marrow 1.01E-12 -0.32 -0.63
------------------------------------------------------------------------------------

References

1 Daratumumab-mediated lysis of primary multiple myeloma cells is enhanced in combination with the human anti-KIR antibody IPH2102 and lenalidomide. Haematologica. 2015 Feb;100(2):263-8.
2 Genetic and antibody-mediated reprogramming of natural killer cell missing-self recognition in vivo. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12879-84.